Fever

ALLIANZ PARTNERS 2024 TRAVEL FORECAST: TRENDS, TIPS AND TRICKS FOR THE BUSY SEASON AHEAD

Retrieved on: 
Thursday, January 11, 2024
Allianz, Candy, Thought, Research, Fever, Nausea, UEFA, Travel, Skiing, Policy, Swimming, Insurance, Common, Water, Season, Ginger, Tourism

Travel demand for 2024 is expected to remain strong with Americans eager to make new memories.

Key Points: 
  • Travel demand for 2024 is expected to remain strong with Americans eager to make new memories.
  • Here's a look ahead at this year's travel landscape with trends from and tips from travel insurance provider Allianz Partners USA with advice on how to handle common vacation mishaps.
  • Allianz Partners offers travel insurance through most major U.S. airlines, leading travel agents, online travel agencies, hotel companies, cruise lines and directly to consumers.
  • For more information on Allianz Partners and available travel policies, please visit http://www.allianztravelinsurance.com/ .

Withings Announces BeamO The Revolutionary At-home Health Checkup

Retrieved on: 
Tuesday, January 9, 2024
LVCC, ECG, Hand, Heart rate, Overalls, Heart, Health, Electrode, Home, Thermoregulation, Atrial fibrillation, LED, History, Arrhythmia, PPG, Skin, Ventricular fibrillation, Movement, Fever, Oxygen saturation (medicine), Future, FDA, Physician, Wi-Fi, CES, Infection, Piezoelectricity, Smartphone, Medical device

With these capabilities, BeamO will conduct a 4-in-1 health checkup of body temperature, heart, and lung health in under a minute.

Key Points: 
  • With these capabilities, BeamO will conduct a 4-in-1 health checkup of body temperature, heart, and lung health in under a minute.
  • By automatically syncing with the Withings app through Wi-Fi, BeamO creates comprehensive health records over time.
  • To better track individual and family health journeys, Withings also introduces new capabilities within the Withings App for BeamO and its entire family of connected health products.
  • A CES Innovations Award Honoree, BeamO will be demoed during CES at the Withings Booth (LVCC NH #8637) .

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Fungal infection, Liver, Marketing, Chills, INN, Risk, Leukopenia, Hypotension, Fungus, Hypertension, Nausea, DNA, Inflammation, Liver disease, Anatomy, IIA, CHMP, Diarrhea, Fever, Infection, ATC, Hepatomegaly, European, Neutrophil, Neoplasm, HIV, Tachycardia, Anemia, Hypocalcemia, Hypokalemia, Patient, Medical Subject Headings, Caspofungin, European Commission, Echinocandin, Kidney failure, International, Bilirubin, Neutropenia, Blood, Language, Thrombocytopenia, Magnesium, Select, Medicine, Vomiting, Phlebitis, Amphotericin B, Allergy, Fluconazole, Headache, Rat, Haematopoiesis, Committee, Checklist, Alkaline phosphatase, Rash, Medical device

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Pritzker Hageman Food Safety Lawyers Investigate Escalating Cantaloupe Salmonella Outbreak

Retrieved on: 
Monday, January 8, 2024
CDC, Family, Trufresh, Fever, Death, Chronic pain, Salmonella, FDA, Diarrhea, Salmonellosis, Health, Pritzker family, Eating, Vaccine

MINNEAPOLIS, Jan. 8, 2024 /PRNewswire/ -- As cases surge across the country, the Pritzker Hageman food safety lawyers are actively investigating the rapidly expanding Salmonella Sundsvall outbreak linked to Machilita and Rudy brand cantaloupe.

Key Points: 
  • MINNEAPOLIS, Jan. 8, 2024 /PRNewswire/ -- As cases surge across the country, the Pritzker Hageman food safety lawyers are actively investigating the rapidly expanding Salmonella Sundsvall outbreak linked to Machilita and Rudy brand cantaloupe.
  • Pritzker Hageman filed the first outbreak lawsuit (case number 1:23-cv-00292-AW-MJF) in December 2023, representing a Florida family whose 13-month-old son contracted a severe Salmonella infection after eating tainted cantaloupe.
  • As the number of cases continues to grow, more Salmonella outbreak lawsuits are expected to follow.
  • The Pritzker Hageman food safety lawyers have represented clients in every major Salmonella outbreak in the country.

Know as They Grow How birth defects affect each stage of life

Retrieved on: 
Monday, January 8, 2024
CDC, Quality of life, Family, Ventricular septal defect, Pregnancy, Birth defect, Risk, Vitamin, Woman, Smoking, Mortality, Health, Diabetes, Intellectual, Prescription, Anencephaly, Genetics, Folate, Spina bifida, Mental health, Birth, Insurance, Prenatal care, COVID-19, Fever, Infection, Anatomical pathology, Infant, Growth, Child, Life, Birth control

Common birth defects include congenital heart defects, cleft lip, cleft palate and spina bifida.

Key Points: 
  • Common birth defects include congenital heart defects, cleft lip, cleft palate and spina bifida.
  • Genetics, behaviors and social and environmental factors can impact the risk for birth defects, and not all birth defects can be prevented.
  • Most doctors recommend women take 400 micrograms of folic acid every day before and during pregnancy to help prevent birth defects.
  • Being obese can increase your baby's chances of having birth defects like neural tube defects, heart defects and cleft palate.

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Patient, Medical Subject Headings, Marketing, Febrile neutropenia, Agency, INN, Fever, Immune system, Risk, Infection, Diffusion, Allergy, DLBCL, ATC, Bone marrow, Cytokine release syndrome, CD20, Platelet, International, Headache, Disease, Neutropenia, Blood, Language, Pleural effusion, Cancer, B-cell lymphoma, Thrombocytopenia, Neutrophil, Rituximab, COVID-19, European Medicines Agency, Select, Bacteria, Anatomy, Anemia, IIA, Sepsis, CD3, Rash, Medical device

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised